Review: A-fib risk up with oral, intravenous bisphosphonates

May 29, 2014
Review: A-fib risk up with oral, intravenous bisphosphonates

(HealthDay)—The risk of atrial fibrillation is increased with use of oral or intravenous bisphosphonates, with a greater risk seen for intravenous versus oral preparations, according to a review published in the June 1 issue of The American Journal of Cardiology.

Abhishek Sharma, M.D., from the Maimonides Medical Center in Brooklyn, N.Y., and colleagues conducted a systematic literature review to examine the incidence of new-onset with use of oral and intravenous . The final analyses included five randomized controlled trials (RCTs) and four , involving 135,347 individuals.

The researchers found observed a significantly increased risk of new-onset atrial fibrillation with intravenous and oral bisphosphonates (relative risks, 1.40 and 1.22, respectively). The risk of atrial fibrillation was higher with intravenous versus oral bisphosphonates, based on the z statistic (P = 0.03).

"In conclusion, pooled data from RCTs and observational studies suggest that risk of atrial fibrillation is increased by use of oral or intravenous bisphosphonates but further suggest that risk is relatively greater with intravenous preparations," the authors write.

Explore further: Female gender increases stroke risk in AF patients aged over 75 years by 20%

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

HRS: Bariatric surgery may prevent A-fib onset in obese

May 8, 2014

(HealthDay)—Bariatric surgery may prevent the development of atrial fibrillation in morbidly obese patients, according to research presented at the annual meeting of the Heart Rhythm Society, held from May 7 to 10 in San ...

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.